Brought to you by 
Biovail takes over Cambridge Labs' tetrabenazine business
16 Jun 2009
Executive Summary
Biovail will pay up to $230mm to buy Cambridge Laboratories' (cancer and CNS drugs) portfolio of tetrabenazine products, associated intellectual property including issued and pending patents, and tetrabenazine drug candidates.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- Product Purchase
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com